Results 141 to 150 of about 76,053 (241)

Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1371-1381, May 2026.
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence‐based treatment decisions.
Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Janine Scholefield, Collen Masimirembwa   +5 more
wiley   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1382-1390, May 2026.
Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the ...
Janine Scholefield, Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Collen Masimirembwa   +5 more
wiley   +1 more source

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai   +10 more
wiley   +1 more source

Zebularine Boosts Imatinib Efficacy in Cells of Colorectal Cancer via Wnt‐Survivin‐P‐Glycoprotein Pathway

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 5, May 2026.
The combination of IM and ZEB showed a promising combination in management of CRC by inducing oxidative stress, promoting apoptosis, and modulating critical genes involved in metastasis and apoptosis. ABSTRACT Colorectal cancer (CRC) remains one of the leading causes of cancer mortality, with a poor survival rate of less than 15%.
Yasmin M. Attia, Abeer Elkhoely, Fatma M. Abdelwahed, Samia A. Shouman, Mervat M. Omran   +4 more
wiley   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. [PDF]

Breast Cancer (Dove Med Press)
Birsin Z, Güren AK, Aliyev V, Guliyev M, Jeral S, Cebeci S, Çerme E, Günaltılı M, Abbasov H, Çiçek E, Atak S, Sarı M, Demirci NS, Alan Ö.   +13 more
europepmc   +1 more source

Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping Review

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with ...
Oluwadamilola Onasanya, Seyed Hamidreza Mahmoudpour, Benjamin Bates, Irene M. Shui, Geoffrey Liu, Eng Hooi Tan, Yi‐Hsin Yang, Maribel Salas, Joseph Fadare, Dimitri Bennett, Paula Lana de M. Drummond, Judy Ju‐Young Shin, Sonia Guleria, Jocelyn R. Wang, Manila Hada, Helene Denis, Soko Setoguchi, Ilse Truter, Luciane C. Lopes, Ruth Wangia Dixon   +19 more
wiley   +1 more source

Health‐related quality of life and functional outcomes of colon cancer patients in the Netherlands: A population‐based study

Colorectal Disease, Volume 28, Issue 5, May 2026.
Abstract Background Colon cancer treatment has evolved significantly through earlier detection, less invasive surgery, optimised perioperative care and shortening chemotherapy duration from 6 to 3 months in 2017. These multidisciplinary improvements may contribute to better health‐related quality of life (HRQoL), yet population‐based data on their real‐
A. J. Pennings, G. R. Vink, S. van Kuijk, M. Koopman, J. Melenhorst, G. L. Beets, A. M. May, S. O. Breukink   +7 more
wiley   +1 more source

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy. [PDF]

Breast Cancer Res Treat
Tavares GM, Ramalho SOB, da Silva LR, Telles GD, de Paiva Silva GR, Torresan RZ, Derchain SFM.   +6 more
europepmc   +1 more source